Article
Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.
Journal of affective disorders - 1 May 2013
Papolos Demitri F, Teicher Martin H, Faedda Gianni L, Murphy Patricia, Mattis Steven
Abstract excerpt
OBJECTIVES: Intravenous ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has been shown to exert a rapid antidepressant effect in adults with treatment resistant depression. Children with bipolar disorder (BD) often respond poorly to pharmacotherapy, including polypharmacy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
